{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:17:04Z","timestamp":1789532224366,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"am","delay-in-days":350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["2P01AG026572"],"award-info":[{"award-number":["2P01AG026572"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["5R25NS107185"],"award-info":[{"award-number":["5R25NS107185"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.amjmed.2022.11.016","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T03:33:25Z","timestamp":1670470405000},"page":"284-293.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Renin-Angiotensin System-Modifying Antihypertensive Drugs Can Reduce the Risk of Cardiovascular Complications in Lupus: A Retrospective Cohort Study"],"prefix":"10.1016","volume":"136","author":[{"given":"Chelsie","family":"Hurst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maira","family":"Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest R.","family":"Vina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen E.","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2022.11.016_bib0001","unstructured":"Centers for Disease Control and Prevention (CDC)]. Systemic lupus erythematosus (SLE). 2018. Available at: https:\/\/www.cdc.gov\/lupus\/facts\/detailed.html. Accessed January 6, 2022."},{"issue":"4","key":"10.1016\/j.amjmed.2022.11.016_bib0002","first-page":"240","article-title":"Lupus: an overview of the disease and management options","volume":"37","author":"Maidhof","year":"2012","journal-title":"P T"},{"issue":"1","key":"10.1016\/j.amjmed.2022.11.016_bib0003","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/antib5010002","article-title":"Autoantibodies in SLE: specificities, isotypes and receptors","volume":"5","author":"Dema","year":"2016","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.amjmed.2022.11.016_bib0004","doi-asserted-by":"crossref","unstructured":"Dein E, Douglas H, Petri M, Law G, Timlin H. Pericarditis in lupus. Cureus. 2019;11(3):e4166.","DOI":"10.7759\/cureus.4166"},{"issue":"1","key":"10.1016\/j.amjmed.2022.11.016_bib0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000335128","article-title":"Mechanisms of pleural involvement in orphan diseases","volume":"83","author":"Anevlavis","year":"2012","journal-title":"Respiration"},{"issue":"4","key":"10.1016\/j.amjmed.2022.11.016_bib0006","first-page":"330","article-title":"Manifestations of systemic lupus erythematosus","volume":"6","author":"Cojocaru","year":"2011","journal-title":"Maedica (Bucur)"},{"issue":"9561","key":"10.1016\/j.amjmed.2022.11.016_bib0007","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0140-6736(07)60279-7","article-title":"Systemic lupus erythematosus","volume":"369","author":"D'Cruz","year":"2007","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.amjmed.2022.11.016_bib0008","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.21955","article-title":"Mortality in systemic lupus erythematosus","volume":"54","author":"Bernatsky","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjmed.2022.11.016_bib0009","unstructured":"Lupus Foundation of America. The leading causes of death in lupus. July 18, 2013. Available at: https:\/\/www.lupus.org\/resources\/the-leading-causes-of-death-in-lupus. Accessed November 6, 2022."},{"issue":"5","key":"10.1016\/j.amjmed.2022.11.016_bib0010","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/0961203307077987","article-title":"Current causes of death in systemic lupus erythematosus in Europe, 2000-2004: relation to disease activity and damage accrual","volume":"16","author":"Nossent","year":"2007","journal-title":"Lupus"},{"issue":"7","key":"10.1016\/j.amjmed.2022.11.016_bib0011","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/jcp.2009.064311","article-title":"Cardiac pathology of systemic lupus erythematosus","volume":"62","author":"Jain","year":"2009","journal-title":"J Clin Pathol"},{"issue":"2","key":"10.1016\/j.amjmed.2022.11.016_bib0012","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1586\/eci.10.98","article-title":"Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention","volume":"7","author":"McMahon","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"10.1016\/j.amjmed.2022.11.016_bib0013","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/heartjnl-2016-309561","article-title":"Incidence and risk of heart failure in systemic lupus erythematosus","volume":"103","author":"Kim","year":"2017","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.amjmed.2022.11.016_bib0014","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/oxfordjournals.aje.a009122","article-title":"Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study","volume":"145","author":"Manzi","year":"1997","journal-title":"Am J Epidemiol"},{"issue":"10","key":"10.1016\/j.amjmed.2022.11.016_bib0015","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1002\/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I","article-title":"Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus","volume":"44","author":"Esdaile","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.amjmed.2022.11.016_bib0016","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.semarthrit.2012.12.002","article-title":"The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review","volume":"43","author":"Schoenfeld","year":"2013","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.amjmed.2022.11.016_bib0017","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.autrev.2017.01.009","article-title":"Subclinical atherosclerosis in systemic lupus erythematosus: comparable risk with diabetes mellitus and rheumatoid arthritis","volume":"16","author":"Tektonidou","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.amjmed.2022.11.016_bib0018","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2174\/157340308784245775","article-title":"Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors","volume":"4","author":"Zeller","year":"2008","journal-title":"Curr Cardiol Rev"},{"issue":"2","key":"10.1016\/j.amjmed.2022.11.016_bib0019","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/CIRCRESAHA.118.313591","article-title":"Immunity and inflammation in atherosclerosis","volume":"124","author":"Wolf","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.amjmed.2022.11.016_bib0020","unstructured":"Whelton SP, Mody FV, McKevoy JW, Martin SS, Blumenthal RS. Cardiovascular risk assessment and allocation of lipid-lowering therapy in patients with chronic inflammatory diseases. June 29, 2017. Available at:https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2017\/06\/29\/08\/22\/cv-risk-assessment-and-allocation-of-lipid-lowering-therapy-in-patients-with-chronic-inflammatory-diseases. Accessed November 5, 2022."},{"issue":"1","key":"10.1016\/j.amjmed.2022.11.016_bib0021","first-page":"15","article-title":"Risk factors in cardiovascular disease in systemic lupus erythematosus","volume":"9","author":"Sinicato","year":"2013","journal-title":"Curr Cardiol Rev"},{"issue":"10","key":"10.1016\/j.amjmed.2022.11.016_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102371","article-title":"Systemic lupus erythematosus and hypertension","volume":"18","author":"Munguia-Realpozo","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.amjmed.2022.11.016_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2017.05.008","article-title":"Cardiovascular disease in systemic lupus erythematosus: a comprehensive update","volume":"82","author":"Giannelou","year":"2017","journal-title":"J Autoimmun"},{"issue":"3","key":"10.1016\/j.amjmed.2022.11.016_bib0024","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.tcm.2017.08.015","article-title":"Heart failure in systemic lupus erythematosus","volume":"28","author":"Dhakal","year":"2018","journal-title":"Trends Cardiovasc Med"},{"issue":"29","key":"10.1016\/j.amjmed.2022.11.016_bib0025","doi-asserted-by":"crossref","first-page":"e1183","DOI":"10.1097\/MD.0000000000001183","article-title":"Cardiovascular events in systemic lupus erythematosus: a nationwide study in Spain from the RELESSER registry","volume":"94","author":"Fern\u00e1ndez-Nebro","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.amjmed.2022.11.016_bib0026","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1177\/0961203311425524","article-title":"Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study","volume":"21","author":"Bengtsson","year":"2012","journal-title":"Lupus"},{"issue":"8","key":"10.1016\/j.amjmed.2022.11.016_bib0027","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1002\/art.24677","article-title":"Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus","volume":"60","author":"McMahon","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.amjmed.2022.11.016_bib0028","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.autrev.2018.02.011","article-title":"The 2018 pipeline of targeted therapies under clinical development for systemic lupus erythematosus: a systematic review of trials","volume":"17","author":"Felten","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.amjmed.2022.11.016_bib0029","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/art.39070","article-title":"Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis","volume":"67","author":"Feldman","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.amjmed.2022.11.016_bib0030","first-page":"620","article-title":"Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14,832 patients with systemic lupus erythematosus: a nested case-control study","volume":"56","author":"Hsu","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.amjmed.2022.11.016_bib0031","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrrheum.2012.14","article-title":"Accelerated atherosclerosis in patients with SLE-mechanisms and management","volume":"8","author":"Skaggs","year":"2012","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.amjmed.2022.11.016_bib0032","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.semarthrit.2013.07.007","article-title":"Do current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients? A critical appraisal","volume":"43","author":"Tselios","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.amjmed.2022.11.016_bib0033","first-page":"713","article-title":"Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95","volume":"31","author":"Bj\u00f6rn\u00e5dal","year":"2004","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.amjmed.2022.11.016_bib0034","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1210\/en.2003-0150","article-title":"Minireview: overview of the renin-angiotensin system\u2014an endocrine and paracrine system","volume":"144","author":"Lavoie","year":"2003","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.amjmed.2022.11.016_bib0035","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/j.2040-4603.2014.tb00567.x","article-title":"Classical renin-angiotensin system in kidney physiology","volume":"4","author":"Sparks","year":"2014","journal-title":"Compr Physiol."},{"issue":"3","key":"10.1016\/j.amjmed.2022.11.016_bib0036","doi-asserted-by":"crossref","first-page":"876","DOI":"10.3390\/ijms19030876","article-title":"Within the brain: the renin angiotensin system","volume":"19","author":"Jackson","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.amjmed.2022.11.016_bib0037","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/sj.jhh.1001960","article-title":"RAS inhibition in hypertension","volume":"20","author":"Ibrahim","year":"2006","journal-title":"J Hum Hypertens"},{"issue":"3","key":"10.1016\/j.amjmed.2022.11.016_bib0038","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.ajkd.2013.06.002","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis","volume":"62","author":"Beck","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.amjmed.2022.11.016_bib0039","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.amjmed.2022.11.016_bib0040","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/rheumatology\/ken208","article-title":"Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus\u2014results from LUMINA (LIX): a multiethnic US cohort","volume":"47","author":"Dur\u00e1n-Barrag\u00e1n","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.amjmed.2022.11.016_bib0041","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.amjmed.2022.11.016_bib0042","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1002\/jcp.27205","article-title":"The potential therapeutic use of renin-angiotensin system inhibitors in the treatment of inflammatory diseases","volume":"234","author":"Ranjbar","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.amjmed.2022.11.016_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.573677","article-title":"Centrally acting angiotensin-converting enzyme inhibitor suppresses type I interferon responses and decreases inflammation in the periphery and the CNS in lupus-prone mice","volume":"11","author":"Nocito","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.amjmed.2022.11.016_bib0044","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1124\/jpet.103.053678","article-title":"Angiotensin inhibition reduces glomerular damage and renal chemokine expression in MRL\/lpr mice","volume":"307","author":"P\u00e9rez de Lema","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"issue":"1-2","key":"10.1016\/j.amjmed.2022.11.016_bib0045","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/BF02003227","article-title":"Differential effects of captopril and enalapril, two angiotensin converting enzyme inhibitors, on immune reactivity in experimental lupus disease","volume":"31","author":"Tarkowski","year":"1990","journal-title":"Agents Actions"},{"issue":"10","key":"10.1016\/j.amjmed.2022.11.016_bib0046","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1084\/jem.20180776","article-title":"Lupus antibodies induce behavioral changes mediated by microglia and blocked by ACE inhibitors","volume":"215","author":"Nestor","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.amjmed.2022.11.016_bib0047","unstructured":"PearlDiver. PearlDiver Mariner Patient Claims Database. Colorado Springs, CO: PearlDiver Technologies. Available at: https:\/\/pearldiverinc.com. Accessed April 19, 2021."},{"issue":"6","key":"10.1016\/j.amjmed.2022.11.016_bib0048","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1177\/0961203309356289","article-title":"Identification and validation of lupus nephritis cases using administrative data","volume":"19","author":"Chibnik","year":"2010","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.amjmed.2022.11.016_bib0049","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/acr.22989","article-title":"Developing electronic heath record algorithms that accurately identify patients with systemic lupus erythematosus","volume":"69","author":"Barnado","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.amjmed.2022.11.016_bib0050","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2147\/CLEP.S245555","article-title":"Validity of claims diagnosis codes for cardiovascular diseases in diabetes patients in Japanese administrative database","volume":"12","author":"Ono","year":"2020","journal-title":"Clin Epidemiol"},{"issue":"7","key":"10.1016\/j.amjmed.2022.11.016_bib0051","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218919","article-title":"A diagnostic accuracy study validating cardiovascular ICD-9-CM codes in healthcare administrative databases. The Umbra Data-Value Project","volume":"14","author":"Cozzolino","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.amjmed.2022.11.016_bib0052","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"1","key":"10.1016\/j.amjmed.2022.11.016_bib0053","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/rheumatology\/keg436","article-title":"Prevention of cardiovascular disease in systemic lupus erythematosus\u2013proposed guidelines for risk factor management","volume":"43","author":"Wajed","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.amjmed.2022.11.016_bib0054","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00296-007-0341-6","article-title":"A pravastatin dose-escalation study in systemic lupus erythematosus","volume":"27","author":"Costenbader","year":"2007","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.amjmed.2022.11.016_bib0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2015.08.030","article-title":"Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based study","volume":"243","author":"Yu","year":"2015","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.amjmed.2022.11.016_bib0056","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/ard.2006.068676","article-title":"Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)","volume":"66","author":"Alarc\u00f3n","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.amjmed.2022.11.016_bib0057","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/art.27289","article-title":"The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus","volume":"62","author":"Jung","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.amjmed.2022.11.016_bib0058","first-page":"325","article-title":"The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs","volume":"26","author":"Rahman","year":"1999","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.amjmed.2022.11.016_bib0059","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.amjmed.2022.11.016_bib0060","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1097\/HJH.0000000000001777","article-title":"Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 - effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis","volume":"36","author":"Thomopoulos","year":"2018","journal-title":"J Hypertens"},{"issue":"10022","key":"10.1016\/j.amjmed.2022.11.016_bib0061","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.amjmed.2022.11.016_bib0062","article-title":"First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension","volume":"11","author":"Chen","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"7653","key":"10.1016\/j.amjmed.2022.11.016_bib0063","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/bmj.39548.738368.BE","article-title":"Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomized trials","volume":"336","author":"Turnbull","year":"2008","journal-title":"BMJ"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934322008683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934322008683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:28:59Z","timestamp":1757582939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934322008683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0002934322008683"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2022.11.016","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renin-Angiotensin System-Modifying Antihypertensive Drugs Can Reduce the Risk of Cardiovascular Complications in Lupus: A Retrospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2022.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}